Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial.
Natia PeradzeOlivia M FarrNikolaos PerakakisIolanda LázaroAleix Sala-VilaChristos S MantzorosPublished in: Cardiovascular diabetology (2019)
Treatment of obese patients without overt type 2 diabetes with high dose of liraglutide for a short period of time induces changes in lipid-lipoprotein and hormonal profile that are suggestive of lower risk of atherosclerosis and CVD. Trial registration ClinicalTrials.gov Identifier: NCT02944500. Study ID Number 2015P000327. Registered November 2016.
Keyphrases
- high dose
- clinical trial
- obese patients
- double blind
- type diabetes
- placebo controlled
- phase ii
- phase iii
- study protocol
- bariatric surgery
- low dose
- cardiovascular disease
- adipose tissue
- randomized controlled trial
- open label
- fatty acid
- metabolic syndrome
- roux en y gastric bypass
- weight loss
- gastric bypass
- insulin resistance
- skeletal muscle
- combination therapy
- low density lipoprotein